Dr. Arranz has dedicated nearly 20 years of research to the identification of genetic determinants of variability in response to CNS drugs, and in particular of antipsychotic medications. Her current research includes genomic and transcriptomic investigations to discern the mechanism of action of drugs. Dr. Arranz's team has published several world-leading papers in the field, and worked on the development of pharmacogenetic tests for the prediction of response to antipsychotics using genetic information. Currently, her team is investigating the clinical and economic benefits of pharmacogenetic interventions for the selection and improvement of antipsychotic and antidepressant treatments.